Staburo recently took part at the workshop of the IBS-DR (Internationale Biometrische Gesellschaft – Deutsche Region) working group “Non-Clinical Statistics”. The workshop was held as hybrid event: Online and at the same time in Ingelheim on 24 and 25 November 2022. It covered many exciting topics in the field of non-clinical statistics like toxicology, design of experiments, process, and stability monitoring.
On a Friday night, 18 Staburo team members, 6 big pizzas, popcorn, a bunch of other snacks, soft drinks, and beer. What could this mean? It was about time for our Staburo team movie night.
Finally, the time had come – some of our colleagues have been waiting for years for this event to happen. Originally it was planned in Friday, 13 (!) March 2020. What happened next is still known to us all.
Staburo Managing Director Hannes Buchner will give a talk about “Applied Biomarker analyses in drug development. Lasso, random forest, longitudinal biomarker analyses” at the colloquium “Statistische Methoden in der empirischen Forschung” (“Statistical methods in empirical research”) at the Freie Universität Berlin on February 14, 2023.
Staburo @ workshop from IBS-DR working group Pharmaceutical Research (APF)
As usual, Staburo took part in the annual workshop of the APF (working group Pharmaceutical Research, of the International Biometric Society German Region) in Berlin on 25 November 2022.
The anticipation for our annual Christmas party was great this year – finally an on-site Christmas party again. In the late afternoon, all Staburo team members met at Marienplatz in Munich. It was time for a city rallye, quizzes and riddles around the old-town, organized by the amazing guides from Weis(s)er Stadtvogel.
Since our team grew substantially, we searched, appointed, and enabled a bigger management team at Staburo, consisting of two heads (of departments) and six directors (focus on data science topics). We want to give them a chance to talk about themselves and their passion! Therefore, we publish a mini news series about the management team members and will continue with our Director Disclosure and Posting, Habib Esmaeili.
Staburo took part in the BVMA symposium on 25 November 2022, at the Westin Grand Hotel, here in Munich. This year it was the 30. BVMA symposium and for this anniversary the get-together took place the evening before at the SEA LIFE aquarium in Munich.
Since our team grew substantially, we searched, appointed, and enabled a bigger management team at Staburo, consisting of two heads (of departments) and six directors (focus on data science topics). We want to give them a chance to talk about themselves and their passion! Therefore, we publish a mini news series about the management team members and will continue with our Director Data Science and Diagnostics, Stefan Bentink.
Staburo’s Managing Director Roland Stieger joined the BIO-Europe last week and enjoyed the great networking opportunities of this partnering conference with approx. 4800 delegates!
In addition to several one-on-one meetings, in which Roland discussed data science challenges of potential partners, there were panel discussions, e.g. about changes in Health Technology Assessment in Europe with Florian Diwischek (Novartis) and Fabian Berkemeier (IGES).
Since our team grew substantially, we searched, appointed, and enabled a bigger management team at Staburo, consisting of two heads (of departments) and six directors (focus on data science topics). We want to give them a chance to talk about themselves and their passion! Therefore, we publish a mini news series about the management team members and will continue with our Head of Business Unit, Katrin Frank.
It is a very nice Staburo tradition to go to the traditional Munich Oktoberfest together. The last two years the “Wiesn” was cancelled but this year it took part again and we decided to go and had a reservation for the Bräurosl tent!
The gold standard for evaluating medical interventions is a randomised clinical trial with statistical analysis based on the intention-to-treat population. However, even if a randomised clinical trial is well planned, post-randomisation events occur and affect or even challenge the interpretation and validity of the study results.